14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
20:31 , Jan 18, 2019 |  BC Week In Review  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
23:28 , Jan 17, 2019 |  BC Extra  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
20:59 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Darzalex combo meets PFS endpoint in first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) and Janssen Biotech Inc. said Darzalex daratumumab plus Revlimid lenalidomide and dexamethasone met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAIA trial to treat newly diagnosed...
17:22 , Jul 27, 2018 |  BC Week In Review  |  Company News

Lee's mulls spin off, HK IPO for China oncology subsidiary

Lee's Pharmaceutical Holdings Ltd. (HKSE:950) said it will consolidate its oncology development pipeline into its China Oncology Focus Ltd. (COF) subsidiary. Lee's CFO Jason Chow told BioCentury that the company expects the reorganization to potentiate...
19:06 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

China advisory committee to review CASI's multiple myeloma therapy

CASI Pharmaceuticals Inc. (NASDAQ:CASI) said China's Expert Advisory Anti-Tumor (Oncology) Drugs Committee will meet to review an application for CASI's Evomela melphalan to treat multiple myeloma. China FDA's Center for Drug Evaluation told CASI the...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
22:06 , Feb 23, 2018 |  BC Extra  |  Company News

Darzalex guidance buoys Genmab shares

Genmab A/S (CSE:GEN; Pink:GMXAY) gained DKK13.6 billion ($2.3 billion) in market cap across two days of trading after issuing an earnings report that included new 2018 guidance for multiple myeloma (MM) drug Darzalex daratumumab. Based...
16:20 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

FDA grants Darzalex Priority Review for first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) said FDA accepted and granted Priority Review to an sBLA from partner Johnson & Johnson (NYSE:JNJ) for Darzalex daratumumab to treat multiple myeloma in the first-line setting. The PDUFA date is...
23:53 , Jan 19, 2018 |  BC Extra  |  Company News

FDA grants Darzalex Priority Review for first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) said FDA accepted and granted Priority Review to an sBLA from partner Johnson & Johnson (NYSE:JNJ) for Darzalex daratumumab to treat multiple myeloma in the first-line setting. The PDUFA date is...